A Double-Blind, Randomized, Prospective Study to Evaluate Adjunctive Risperidone Versus Adjunctive Placebo in Generalized Anxiety Disorder Sub-Optimally Responsive to Standard Psychotropic Therapy.
Phase of Trial: Phase III
Latest Information Update: 04 May 2010
At a glance
- Drugs Risperidone (Primary)
- Indications Generalised anxiety disorder
- Focus Registrational; Therapeutic Use
- 05 May 2009 Actual patient number (301) and actual end date (1 Jun 2005) added as reported by ClinicalTrials.gov.
- 25 Oct 2007 Status changed from in progress to completed.
- 09 Oct 2005 New trial record.